Skip to content

US · KMDA · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Kamada Ltd. (KMDA) intrinsic value and stock valuation

$7.74as of 2026-11-21 · Mkt cap 414.24M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kamada Ltd. DCF and intrinsic value

InvestorsCraft values KMDA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from KMDA’s statements →

Kamada Ltd. Graham Number

Graham Number: $6.07d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Rehovot, HM 7670402 kamada.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$180.5M+6.3% 5y CAGRd
20112025
Net income
$20.2M+3.3% 5y CAGRd
20112025
Free cash flow
$16.9M+4.4% 5y CAGRd
20112025
Total equity
$269.1M+8.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$180.5M$161M$142.5M$129.3M$103.6M
Operating income$26.2M$20.1M$10.1M$4.53M-$-700K
Net income$20.2M$14.5M$8.28M-$-2.32M-$-2.23M
EPSd$346.2K$250.1K$154.2K-$-51.76K-$-49.81K
Operating cash flow$27.6M$47.6M$4.32M$28.6M-$-9.17M
Capital expenditure-$-10.66M-$-10.74M-$-5.85M-$-3.78M-$-3.88M
Free cash flow$16.9M$36.9M-$-1.53M$24.8M-$-13.04M
Total assets$378.8M$372.3M$354.9M$322.4M$318.7M
Total debt$11.6M$11.1M$8.82M$20.6M$24.4M
Net debt-$-63.92M-$-67.37M-$-46.82M-$-13.66M$5.76M
Total equity$269.1M$259.5M$244M$176M$176.8M
Cash and short-term investments$75.5M$78.4M$55.6M$34.3M$18.6M
Income statement
20252024202320222021
Revenue$180.5M$161M$142.5M$129.3M$103.6M
Cost of revenue$104.1M$91M$87M$82.6M$73.3M
Gross profit$76.4M$70M$55.5M$46.7M$30.3M
Research and development expenses$13M$15.2M$13.9M$13.2M$11.4M
Selling, general and administrative expenses$33.8M$30.8M$27.5M$25.1M$17.6M
Other expenses$3.34M$3.9M$4.04M$3.94M$2.12M
Operating expenses$50.2M$49.9M$45.4M$42.2M$31M
Cost and expenses$154.2M$140.9M$132.5M$124.8M$104.3M
Interest income$1.92M$2.12M$590K$90K$290K
Interest expense$860K$660K$1.3M$910K$280K
Depreciation and amortization$14.9M$13.8M$11.5M$12.2M$5.61M
Ebitda$39.3M$27.8M$21.2M$10.8M$4.01M
Operating income$26.2M$20.1M$10.1M$4.53M-$-700K
Total other income/expenses, net-$-2.77M-$-6.72M-$-1.64M-$-6.79M-$-1.19M
Income before tax$23.5M$13.3M$8.43M-$-2.26M-$-1.89M
Income tax expense$3.27M-$-1.13M$140K$60K$340K
Net income$20.2M$14.5M$8.28M-$-2.32M-$-2.23M
Weighted average shares outstanding$57.7M$57.5M$48.8M$44.8M$44.8M
Weighted average diluted shares outstanding$58.4M$57.8M$53.7M$44.8M$44.8M
Balance sheet
20252024202320222021
Cash and short-term investments$75.5M$78.4M$55.6M$34.3M$18.6M
Net receivables$29.1M$23.2M$21.3M$28.4M$35.6M
Inventory$85M$78.8M$88.5M$72.5M$71.8M
Total current assets$193.1M$184.4M$170M$139M$130M
Property, plant and equipment, net$50.3M$45.9M$36M$28.7M$29.4M
Goodwill and intangible assets$126.4M$132.2M$140M$147M$153.6M
Long-term investments$7.55M$0.00$0.00$0.00$0.00
Total non-current assets$185.7M$187.9M$184.9M$183.4M$188.6M
Total assets$378.8M$372.3M$354.9M$322.4M$318.7M
Accounts payable$23.3M$27.7M$24.8M$32.9M$25.1M
Short-term debt$2.12M$1.63M$1.38M$5.46M$3.79M
Deferred revenue$0.00$170K$330K$240K$250K
Total current liabilities$47.4M$49.4M$49.6M$75.7M$54.1M
Long-term debt$9.44M$9.43M$7.44M$15.1M$20.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$10K
Total non-current liabilities$62.3M$63.4M$61.3M$70.7M$87.8M
Capital lease obligations$9.44M$11.1M$8.82M$3.19M$4.31M
Total liabilities$109.7M$112.8M$110.9M$146.4M$141.8M
Common stock$15.1M$15M$15M$11.7M$11.7M
Retained earnings-$-17.08M-$-25.74M-$-40.2M-$-48.48M-$-46.16M
Accumulated other comprehensive income (loss)$2.78M-$-3.08M-$-3.08M-$-3.23M-$-3.58M
Total equity$269.1M$259.5M$244M$176M$176.8M
Total investments$7.55M$0.00$0.00$0.00$0.00
Total debt$11.6M$11.1M$8.82M$20.6M$24.4M
Net debt-$-63.92M-$-67.37M-$-46.82M-$-13.66M$5.76M
Cash flow statement
20252024202320222021
Net income$21.9M$14.5M$8.28M-$-2.32M-$-2.32M
Depreciation and amortization$16.2M$13.8M$12.7M$12.2M$5.83M
Stock-based compensation$0.00$870K$1.31M$1.15M$0.00
Change in working capital-$-19.14M$11.4M-$-18.2M$11.7M-$-14.98M
Accounts receivable-$-5.92M-$-910K$9.5M$5.68M-$-15.07M
Inventory-$-6.63M$9.66M-$-19.69M-$-1.36M-$-2.47M
Accounts payable-$-7.44M$1.23M-$-8.88M$7.05M$8.23M
Net cash provided by operating activities$27.6M$47.6M$4.32M$28.6M-$-9.17M
Investments in property, plant and equipment-$-10.66M-$-10.74M-$-5.85M-$-3.78M-$-3.88M
Acquisitions, net$10K$0.00$0.00$0.00-$-100.21M
Net cash used for investing activities-$-10.65M-$-10.74M-$-5.84M-$-3.78M-$-63.46M
Common stock issued$50K$0.00$58.2M$0.00$20K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-12.49M$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-19.86M-$-13.91M$22.7M-$-9.34M$19.3M
Net change in cash-$-2.95M$22.8M$21.4M$15.7M-$-51.58M
Cash at end of period$75.5M$78.4M$55.6M$34.3M$18.6M
Operating cash flow$27.6M$47.6M$4.32M$28.6M-$-9.17M
Capital expenditure-$-10.66M-$-10.74M-$-5.85M-$-3.78M-$-3.88M
Free cash flow$16.9M$36.9M-$-1.53M$24.8M-$-13.04M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kamada Ltd.

        Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.

        CEO
        Amir London
        Employees
        462
        Beta
        0.15

        Explore

        Frequently asked questions

        What is the intrinsic value of Kamada Ltd. (KMDA)?

        Kamada Ltd. (KMDA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is KMDA undervalued?

        KMDA trades at a price of $7.74 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.